Genmab — Januar 2019
-
Will MorphoSys win the Darzalex patent case against Janssen and Genmab? — Markman Advisors
In 2016, MorphoSys ($MOR) sued Janssen ($JNJ) and Genmab for patent infringement. MorphoSys claims that Janssen’s anti-CD38 antibody, Darzalex®, infringes three of its patents. The case is scheduled to go to trial in February 2019. The stakes are big because the patents purport to cover the actual protein used in Darzalex®, which could mean material royalty rates on sales of Janssen’s drug. What are the strengths and weaknesses of each party’s case?
Markman Advisors (www.markmanadvisors.com)
-
Det mener jeg også at kunne huske.
-
-
JnJ hæver priserne, men forventer lavere nettopriser https://www.reuters.com/article/us-johnson-johnson-drugpricing/jj-raises-u-s-prices-on-around-two-dozen-drugs-idUSKCN1P42VY?il=0
-
-
Ummiddelbart vil jeg ret logisk mene at der ikke er behov for "humanization" af et antistof, hvis udgangspunktet er et human antistof. Modsat, hvis antistoffet stammer fra andre organismer (mus, hamster, disse bruges ofte) er der behov for "humanization" for at undgå en immuno respons mod antistoffet.
-
Genmab har jo altid pointeret at Dara er et human IgG1k monoclonal antibody. https://www.creativebiolabs.net/Anti-Human-CD38-Therapeutic-Antibody-Daratumumab-13615.htm?gclid=Cj0KCQiAmuHhBRD0ARIsAFWyPwj-CJ18ql8PFDwELsRXUJ9_BlPn_dRCSNOFVcVHXDVo_PtSzRbi-nIaAhTVEALw_wcB
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind